Anika Therapeutics Inc. · NASDAQ:ANIK
Anika Therapeutics — Q3 2016 Earnings Presentation
10 slides from Anika Therapeutics's earnings presentation, Oct 27, 2016
Slide 1: Anika Therapeutics Third Quarter 2016 Earnings Call Presentation
ANIKA THERAPEUTICS, INC. Third Quarter 2016 Earnings Call Presentation October 27, 2016
Slide 2: Safe Harbor Statement
SAFE HARBOR STATEMENT The statements made in this presentation that are not statements of historical fact are forward looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward- looking statements involve known a
Slide 3: Update on Discussions with FDA on CINGAL
UPDATE ON DISCUSSIONS WITH FDA ON CINGAL • Met with the FDA in Late September 2016 • Achieved Alignment on an Overall Approval Framework • Working Toward Finalization of Detailed Approval Requirements • Expect CINGAL IND Application by Early 2017 3
Slide 4: Long-Term Growth Strategy
LONG-TERM GROWTH STRATEGY Expanding Advancing Strengthening Strategic Globally Pipeline Infrastructure M&A 4
Slide 5: Expanding Globally
EXPANDING GLOBALLY • Commercial Launch of CINGAL in Canada and Europe Continues Currently Available in Approximately Ten International Countries Regulatory Packages for India and Australia Expected to be Submitted by Year-end 2016 “Reactions are unanimous and very positive about not only how qui
Slide 6: Advancing Pipeline
ADVANCING PIPELINE Product Stage of Development Market Candidate Indication (For U.S. Approval) Ex-U.S. Approvals Opportunity Knee Approved in Phase III to Commence ~$2 B Osteoarthritis Canada & E.U. Approved in Hip Phase III Canada, E.U. & ~$600 M Osteoarthritis Other Intl. Countries Cartilage Appr
Slide 7: Advancing Pipeline
ADVANCING PIPELINE * • Non-woven HA Biodegradable 3D Scaffold for Cartilage * In Pipeline in the U.S.; Approved in E.U. Repair • Cost-effective Single-step Procedure for the Repair of Articular Cartilage Defects • Over 7,000 Treated with HYALOFAST Internationally • FastTRACK Phase III Trial Ongoing
Slide 8: Strengthening Infrastructure
STRENGTHENING INFRASTRUCTURE • Integration of Solid HA Manufacturing Operations is Progressing as Planned Build-out of the Bedford Facility has been Completed Solid HA Product Packaging Operations Expected to be Online by Early 2017 Fully Operational with Regulatory Approvals for Contract Manu
Slide 9: Delivering Strong Growth
DELIVERING STRONG GROWTH Q3 & YTD 2016 Financial Highlights Q3 Q3 YTD YTD • Total revenue increased 9% 2015 2016 2015 2016 year-over-year; 20% year-to-date Total Revenue $23.7 $25.8 $62.1 $74.7 • Orthobiologics revenue grew 10% year-over-year; 26% year-to-date Net Income $8.4 $9.0 $19.7 $24.5 • Net
Slide 10: Q&A
Q&A Anika Therapeutics, Inc. Third Quarter 2016 Earnings Call Presentation October 27, 2016